Technology Appraisals Endorsement Process
The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland. The new arrangements are detailed in following circulars, which is effective from 18th December 2013;
NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13.
For information, details of the previous arrangement can be found on the following circular;
NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11
2022/2023
The following technology appraisals have been endorsed during 2021/22. Information on technology appraisals endorsed in previous years can be found on the homepage.
March 2023
TA874 - Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma
TA873 - Cannabidiol for treating seizures caused by tuberous sclerosis complex
‘Note this guidance updates and replaces NICE Technology Appraisal TA559, endorsed by the DoH in April 2019.’
TA871 - Eptinezumab for preventing migraine
'Note this guidance updates and replaces NICE Technology Appraisal TA505, endorsed by the DoH in February 2019.'
TA868 - Vutrisiran for treating hereditary transthyretin-related amyloidosis
TA866 - Regorafenib for previously treated metastatic colorectal cancer
February 2023
‘Note this guidance partially replaces NICE Technology Appraisal TA379, endorsed by the DoH in February 2016.’
TA861 - Upadacitinib for treating active non-radiographic axial spondyloarthritis
TA860 - Maribavir for treating refractory cytomegalovirus infection after transplant
TA858 - Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma
January 2023
TA856 - Upadacitinib for treating moderately to severely active ulcerative colitis
TA854 - Esketamine nasal spray for treatment-resistant depression
TA853 - Avatrombopag for treating primary chronic immune thrombocytopenia
‘Note this guidance updates and replaces NICE Technology Appraisal TA669, which was endorsed by the DoH in February 2021.’
TA849 - Cabozantinib for previously treated advanced hepatocellular carcinoma
December 2022
November 2022
TA837 - Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma
‘Note this guidance updates and replaces NICE Technology Appraisal TA619, which was endorsed by the DoH in February 2020.’
TA835 - Fostamatinib for treating refractory chronic immune thrombocytopenia
‘Note this guidance updates and replaces NICE Technology Appraisal TA759, which was endorsed by the DoH in February 2022.’
TA833 - Zanubrutinib for treating Waldenstrom’s macroglobulinaemia
TA830 - Pembrolizumab for adjuvant treatment of renal cell carcinoma
October 2022
‘Note this guidance has been updated and replaced by TA887 - Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer, endorsed by the DoH in June 2023.’
TA829 - Upadacitinib for treating active ankylosing spondylitis
TA828 - Ozanimod for treating moderately to severely active ulcerative colitis
TA824 - Dexamethasone intravitreal implant for treating diabetic macular oedema - Note this guidance updates and replaces NICE Technology Appraisal TA349, which was endorsed by the DoH in August 2015.
TA823 - Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer
TA800 - Faricimab for treating wet age-related macular degeneration
TA799 - Faricimab for treating diabetic macular oedema
September 2022
TA821 - Avalglucosidase alfa for treating Pompe disease
TA820 - Brolucizumab for treating diabetic macular oedema
TA818 - Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma
TA817 - Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence
TA815 - Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs
'Note this guidance updates and replaces NICE Technology Appraisal TA711, which was endorsed by the DoH in July 2021'
TA814 - Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis
TA813 - Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors
August 2022
TA812 - Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer
TA808 - Fenfluramine for treating seizures associated with Dravet syndrome
TA807 - Roxadustat for treating symptomatic anaemia in chronic kidney disease
TA803 - Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs
July 2022
TA804 - Teduglutide for treating short bowel syndrome
TA802 - Cemiplimab for treating advanced cutaneous squamous cell carcinoma
‘Note this guidance updates and replaces NICE Technology Appraisal TA592, which was endorsed by the DoH in September 2019’
‘Note this guidance updates and replaces NICE Technology Appraisal TA578, which was endorsed by the DoH in May 2019’
TA796 - Venetoclax for treating chronic lymphocytic leukaemia
‘Note this guidance updates and replaces NICE Technology Appraisal TA487, which was endorsed by the DoH in February 2019’
TA795 - Ibrutinib for treating Waldenstrom’s macroglobulinaemia
‘Note this guidance updates and replaces NICE Technology Appraisal TA491, which was endorsed by the DoH in February 2019’
TA794 - Diroximel fumarate for treating relapsing–remitting multiple sclerosis
June 2022
TA792 - Filgotinib for treating moderately to severely active ulcerative colitis
TA791 - Romosozumab for treating severe osteoporosis
TA789 - Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations
May 2022
‘Note this guidance updates and replaces NICE Technology Appraisal TA528, which was endorsed by the DoH in January 2019’.
April 2022
TA783 - Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
‘Note this guidance updates and replaces NICE Technology Appraisal TA510, which was endorsed by the DoH in February 2019’.
TA780 - Nivolumab with ipilimumab for untreated advanced renal cell carcinoma Note this guidance updates and replaces NICE Technology Appraisal TA581, which was endorsed by the DoH in June 2019